TDP43 promotes stemness of breast cancer stem cells through CD44 variant splicing isoforms

Alternative splicing (AS) is a promising clinical target for cancer treatment at the post-transcriptional level. We previously identified a unique AS profile in triple-negative breast cancer (TNBC), which is regulated by the splicing regulator TAR DNA-binding protein-43 (TDP43), thus indicating the...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, Lu, Ke, Hao, Zhang, Honglei, Zou, Li, Yang, Qin, Lu, Xuemei, Zhao, Limin, Jiao, Baowei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9065105/
https://www.ncbi.nlm.nih.gov/pubmed/35504883
http://dx.doi.org/10.1038/s41419-022-04867-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9065105/
https://www.ncbi.nlm.nih.gov/pubmed/35504883
http://dx.doi.org/10.1038/s41419-022-04867-w

Ejemplares similares